JO
ALLO icon

John Overdeck’s Allogene Therapeutics ALLO Stock Holding History

John Overdeck’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.2M Buy
7,784,348
+2,408,892
+45% +$5.29M 0.01% 1185
2026
Q1 		$13.1M Buy
5,375,456
+1,952,015
+57% +$3.91M 0.01% 1226
2025
Q4 		$4.69M Buy
3,423,441
+39,797
+1% +$52.5K 0.01% 1770
2025
Q3 		$4.2M Buy
3,383,644
+1,770,419
+110% +$2.11M 0.01% 1594
2025
Q2 		$1.82M Sell
1,613,225
-461,874
-22% -$614K ﹤0.01% 1897
2025
Q1 		$3.03M Sell
2,075,099
-637,040
-23% -$1.2M 0.01% 1452
2024
Q4 		$5.78M Sell
2,712,139
-85,831
-3% -$212K 0.01% 1020
2024
Q3 		$7.83M Sell
2,797,970
-162,703
-5% -$434K 0.02% 864
2024
Q2 		$6.9M Buy
2,960,673
+1,049,335
+55% +$3.1M 0.02% 868
2024
Q1 		$8.54M Sell
1,911,338
-403,203
-17% -$1.68M 0.02% 714
2023
Q4 		$7.43M Buy
2,314,541
+1,014,320
+78% +$2.88M 0.02% 802
2023
Q3 		$4.12M Sell
1,300,221
-652,559
-33% -$2.86M 0.01% 998
2023
Q2 		$9.71M Buy
1,952,780
+76,031
+4% +$411K 0.02% 656
2023
Q1 		$9.27M Buy
1,876,749
+265,497
+16% +$1.7M 0.03% 616
2022
Q4 		$10.1M Buy
1,611,252
+778,288
+93% +$7.21M 0.03% 550
2022
Q3 		$9M Buy
832,964
+673,886
+424% +$9.16M 0.03% 526
2022
Q2 		$1.81M Sell
159,078
-795,086
-83% -$7.06M 0.01% 1252
2022
Q1 		$8.69M Buy
954,164
+764,373
+403% +$7.96M 0.03% 664
2021
Q4 		$2.83M Buy
+189,791
New +$3.35M 0.01% 1613
2021
Q3 		– Sell
-31,359
Closed -$818K – 4203
2021
Q2 		$818K Sell
31,359
-161,179
-84% -$4.6M ﹤0.01% 2659
2021
Q1 		$6.8M Sell
192,538
-151,086
-44% -$5.1M 0.02% 888
2020
Q4 		$8.67M Sell
343,624
-21,024
-6% -$685K 0.02% 658
2020
Q3 		$13.8M Buy
364,648
+111,255
+44% +$4.19M 0.05% 408
2020
Q2 		$10.8M Buy
+253,393
New +$9.16M 0.05% 365

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

John Overdeck's ALLO Position: Q2 2026 in Review

John Overdeck increased its Allogene Therapeutics (ALLO) stake by 45% in Q2 2026, buying an estimated $5.29M and bringing the position to 7,784,348 shares worth $16.2M. The position accounts for 0.01% of the portfolio, ranked #1185.

John Overdeck first reported a position in ALLO in Q2 2020 and has held it in 24 quarters since. 207 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • John Overdeck held 7,784,348 shares of Allogene Therapeutics worth $16.2M as of Q2 2026.
  • John Overdeck bought 2,408,892 Allogene Therapeutics shares in Q2 2026, an estimated $5.29M.
  • Allogene Therapeutics made up 0.01% of John Overdeck's portfolio in Q2 2026, its #1185 holding.
  • John Overdeck first reported a position in Allogene Therapeutics in Q2 2020 and has held it in 24 quarters since.
  • 207 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.